Royalty Pharma vs Sarepta Therapeutics
RPRX and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RPRX and SRPT compare
Royalty Pharma is the larger company, worth 23 times as much as Sarepta Therapeutics ($39.9B against $1.7B).
Royalty Pharma grew revenue faster over the last twelve months (11.4% versus −18.9% for Sarepta Therapeutics).
Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 25.7% compared with −5.9% at Sarepta Therapeutics.
Royalty Pharma pays a dividend yielding 1.7%; Sarepta Therapeutics does not pay one.
Sarepta Therapeutics scores higher on the StockData Score (11 against 8 for Royalty Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RPRX | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $39.9B | $1.7B |
| Share price | $69.31 | $16.07 |
| Change, 1 year | 75.1% | −10.7% |
| Change, 5 years | 66.8% | −79.9% |
| Beta (5Y) | 0.41 | 0.99 |
| Employees | 100 | 835 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 2 (better) | 0 |
| Valuation | ||
| P/E | 48.8× | – |
| P/S | 15.2× | 0.9× (better) |
| P/B | – | 1.1× |
| EV/EBITDA | 34.0× | – |
| P/FCF | – | 9.6× |
| PEG | 0.30 | – |
| FCF yield | – | 10.4% |
| Fair value | $43.25 | $104.78 |
| Margin of safety | −60.3% | 84.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.4% (better) | −18.9% |
| Revenue growth, 5Y average | 2.3% | 32.4% (better) |
| Net income growth (TTM) | −12.0% | – |
| EPS growth (TTM) | −12.9% | – |
| EPS growth, 5Y average | 6.2% | – |
| Profitability | ||
| Operating margin | 57.1% (better) | −2.5% |
| Net margin | 25.7% (better) | −5.9% |
| FCF margin | – | 9.0% |
| Return on equity | – | −7.6% |
| Return on invested capital | – | −5.3% |
| Financial health | ||
| Debt / equity | – | 0.10 |
| Net debt / EBITDA | 5.38 | – |
| Interest coverage | 4.0× | – |
| Current ratio | 1.29 | 3.46 (better) |
| Altman Z-score | 3.06 (better) | −0.22 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | – |
| Buyback yield | 0.66% | – |
| Shareholder yield | 2.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 63.8% | 102% |
| Held by insiders | 22.6% | 5.9% |
| Insider net buying, 12 months | −$82.2M | −$417K (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 2.9% | 19.4% |
Go deeper
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.